Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $30 to $42.
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $30 to $42.